Education
About Us
Working with TipRanks
Follow Us
Novavax (NVAX)
NASDAQ:NVAX
NVAX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.43 - $23.86
Previous CloseN/A
Volume4.15M
Average Volume (3M)6.12M
Market Cap
$1.03B
Enterprise Value$618.06M
Total Cash (Recent Filing)$14.57M
Total Debt (Recent Filing)$460.00K
Price to Earnings (P/E)―
Beta1.60
Next Earnings
May 07, 2025EPS Estimate
0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.32
Shares Outstanding160,844,200
10 Day Avg. Volume6,692,701
30 Day Avg. Volume6,121,657
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.60
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.29
Enterprise Value/Ebitda-5.72
Forecast
1Y Price Target
$14.25Price Target Upside122.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
---
Bulls Say, Bears Say
Bulls Say
Market PotentialThe potential combination of Novavax's Covid vaccine with high-dose flu vaccines represents a significant potential upside for Novavax.
Regulatory ApprovalNovavax highlighted that they believe their BLA for Nuvaxovid is approvable based on their conversations with the FDA to date.
Vaccine SafetyThe Novavax vaccine resulted in about half as many negative symptoms compared to current mRNA vaccines, which could be advantageous in the Covid vaccination landscape.
Bears Say
Financial RisksSignificant downside risk is seen if Novavax doesn’t secure full approval for milestones and royalties from the Sanofi partnership.
Regulatory Approval DelaysThe announcement of a pause on the pending BLA review of Nuvaxovid is seen as confirming one of the biggest near-term risks for the industry flagged by investors.
Regulatory ChallengesThe request for another randomized clinical trial for Nuvaxovid increases downside risk for potential milestones/royalties.
---
Ownership Overview
0.40% Insiders
12.76% Mutual Funds
0.01% Other Institutional Investors
69.37% Public Companies and
Individual Investors
NVAX FAQ
What was Novavax’s price range in the past 12 months?
Novavax lowest stock price was $4.43 and its highest was $23.86 in the past 12 months.
What is Novavax’s market cap?
Novavax’s market cap is $1.03B.
When is Novavax’s upcoming earnings report date?
Novavax’s upcoming earnings report date is May 07, 2025 which is in 4 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on Feb 27, 2025. The company reported -$0.51 earnings per share for the quarter, beating the consensus estimate of -$0.514 by $0.004.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Undervalued.
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is 0.19.
How many shares outstanding does Novavax have?
Novavax has 160,844,200 shares outstanding.
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of -$0.51 in its last earnings report, beating expectations of -$0.514. Following the earnings report the stock price went down -3.552%.
Which hedge fund is a major shareholder of Novavax?
Currently, no hedge funds are holding shares in NVAX
---
Novavax Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.25 (122.31% Upside)
$14.25 (122.31% Upside)
Blogger Sentiment
Bullish
NVAX Sentiment 80%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $119.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.1%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
54.04%
12-Months-Change
Fundamentals
Return on Equity
30.06%
Trailing 12-Months
Asset Growth
-13.62%
Trailing 12-Months
Company Description
Novavax
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
---
NVAX Company Deck
---
NVAX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlights several positive strategic moves by Novavax, including a significant partnership with Sanofi, financial improvements, and new pipeline initiatives. However, these are counterbalanced by challenges such as declining revenues, dependence on Sanofi for future success, and regulatory uncertainties.Read More>---
NVAX Stock 12 Month Forecast
Average Price Target
$14.25
▲(122.31% Upside)
Technical Analysis
Anavex Life Sciences
―
CureVac
―
AbCellera Biologics
―
Pharvaris
―
Immunocore Holdings
―
---